Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297 別名:Mereletinib

Osimertinib (AZD9291)化学構造

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ 価格(税別)  
JPY 18100
JPY 24400
JPY 118200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(237)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明 Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
特性 Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
ターゲット
L858R/T790M EGFR [1]
(LoVo cells)
Exon 19 deletion EGFR [1]
(LoVo cells)
WT EGFR [1]
(LoVo cells)
11.44 nM 12.92 nM 493.8 nM
体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-9/BRc1 M2mzO2Z2dmO2aX;uJGF{e2G7 NV3TPFR3PTBibl2= M3HNcFI1KGh? NHn5WXNFVVOR MmjIbY5lfWOnczDlfJBz\XO|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2= M1TseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N|I2Lz5{NUS3O|MzPTxxYU6=
PC-9/ERc1 NFmyZW5HfW6ldHnvckBCe3OjeR?= NHj6fZE2OCCwTR?= MnzENlQhcA>? NUTlWZZyTE2VTx?= MY\pcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= NVPpWHptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2 Mo\DSpVv[3Srb36gRZN{[Xl? MlnmOVAhdk1? NHr0PFEzPCCq NUm2RW11TE2VTx?= M1HPRolv\HWlZYOg[ZhxemW|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN NYLvTHZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1 M4TBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPuUms2OCCwTR?= MUGxNEBl Mn7TSG1UVw>? MkDIbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm| M37i[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N|I2Lz5{NUS3O|MzPTxxYU6=
PC-9/ERc1 M4PXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLqOVAhdk1? NF6xe|cyOCCm NY\pPVlPTE2VTx?= NIX6bZFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TXUFUxKG6P NVLQ[nY1OTBiZB?= NX[zNnJFTE2VTx?= NH3scZRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO= Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
PC9 GR4 MlWxSpVv[3Srb36gRZN{[Xl? MW[wMVExKM7:TR?= MYS3NkBp NVr2[5ExcW6qaXLpeJPDqEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\8Li M{TScFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 Mnm5SpVv[3Srb36gRZN{[Xl? M4rrfVAuOTBizszN MV23NkBp M1e2SIlvcGmkaYTzJHdVKEWJRmKgZZQhdG:5IHPvcoNmdnS{YYTpc45{ M{G2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 GR4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiwMVExKM7:TR?= M3\BelczKGh? NW[5e3RpcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N|M9N2F-
BAF3 M4TPWWZ2dmO2aX;uJIF{e2G7 Mnu5O|IhcA>? MmHOS2k2OCB;IECuNFAxOyEQvF2= MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3 Mke3SpVv[3Srb36gZZN{[Xl? MYi3NkBp NHjQO2tIUTVyIE2gNE4xODB|IN88US=> M{S2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3 MYLGeY5kfGmxbjDhd5NigQ>? MX:3NkBp NULE[4RHT0l3MDC9JFAvODBzIN88US=> M3n2b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827 NEjqN3JHfW6ldHnvckBie3OjeR?= MknLO|IhcA>? MkDRS2k2OCB;IECuNFAyKM7:TR?= Mn7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9 MljYSpVv[3Srb36gZZN{[Xl? NGPiTXM4OiCq NY\yR2lPT0l3MDC9JFAvODB{IN88US=> M3XD[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3 NWO3TpZ7TnWwY4Tpc44h[XO|YYm= MmLrOEBp M2jqZWVEPTBiPTCwMlAxOiEQvF2= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 NIfSb4pHfW6ldHnvckBie3OjeR?= M2\xXVMhcA>? MYLJR|UxKD1iMD6wNFI2KM7:TR?= NHfRb4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN|gzQSd-Mke0N|M5Ojl:L3G+
H1975 M4\pfGZ2dmO2aX;uJIF{e2G7 NEDCcGo{KGh? NHnRVYdKSzVyIE2gNE4xODJ3IN88US=> M1qzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN|gzQTxxYU6=
H3255 MVvGeY5kfGmxbjDhd5NigQ>? MYqzJIg> M4\1dGlEPTBiPTCwMlAxPDFizszN MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
NCI-H1975 NGrCNppHfW6ldHnvckBie3OjeR?= MXu3NkBp Mn7YS2k2OCB;IECuNFA2KM7:TR?= NYnxcWhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9 MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MnKzO|IhcA>? M3PI[mlEPTBiPTCwMlAxPjVizszN MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975 NXL0bYdXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NV\0bVJ6PzJiaB?= NYPGOmhoUUN3MDC9JFAvODFyNTFOwG0> M2W0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
Sf21 MUnGeY5kfGmxbjDhd5NigQ>? NFracIRKSzVyIE2gNE4xOTJizszN NGDGVZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
PC9-DRH MoWxSpVv[3Srb36gZZN{[Xl? MUOyJIg> MVPJR|UxKD1iMD6wNVMh|ryP M2rROVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
BAF3 MkO3SpVv[3Srb36gZZN{[Xl? M4X3blczKGh? NVjRdHYzT0l3MDC9JFAvODF|IN88US=> NV:wcItiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827 MnTHSpVv[3Srb36gZZN{[Xl? MnTVPVYhcA>? MYLFR|UxKD1iMD6wNVQh|ryP NWT2U2tLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
HCC827 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NIXWZVE6PiCq NEjWRpJGSzVyIE2gNE4xOTRizszN M3:y[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
NCI-H1975 M3S3R2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MoPjPVYhcA>? M1ezZWVEPTBiPTCwMlAyPCEQvF2= NGLRN|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975 M1PpSmZ2dmO2aX;uJIF{e2G7 M4T0U|IhcA>? NXrVToxoUUN3MDC9JFAvODF3IN88US=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
H1975 NYnobnB6TnWwY4Tpc44h[XO|YYm= MU[yJIg> MlvDTWM2OCB;IECuNFE2KM7:TR?= NYDIWmpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV|PD;hQi=>
PC9 M1\rWmZ2dmO2aX;uJIF{e2G7 NWDCdIZTOiCq MXjJR|UxKD1iMD6wNVch|ryP M{HvfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
NCI-H1975 NXnYOZhRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MmrYO|IhcA>? MVzJR|UxKD1iMD6wNVkh|ryP M3WzN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O|c{Lz5{OUS2Olc4OzxxYU6=
NCI-H1975 NWT6eGZTTnWwY4Tpc44h[XO|YYm= NVntOmo1QTZiaB?= NGjS[XZGSzVyIE2gNE4xOTlizszN MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
NCI-H1975 Mk\pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NXHiU5FMQTZiaB?= MnSzSWM2OCB;IECuNFE6KM7:TR?= NVT2W21YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NFM6QTFpPkK4OlA{QTlzPD;hQi=>
NCI-H1975 NH\ye45CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MVu3NkBp M{DWV2lEPTBiPTCwMlAyQSEQvF2= MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
HCC827 NUP5UVFpTnWwY4Tpc44h[XO|YYm= MVuyJIg> NFvlUlFKSzVyIE2gNE4xOjNizszN MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
NCI-H1975 NYHvXIlySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NWHERZBFPzJiaB?= NUL5SYlIUUN3MDC9JFAvODJ|IN88US=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV|NEmyOkc,Ojl3M{S5NlY9N2F-
PC9 MoDsR5l1d3SxeHnjbZR6KGG|c3H5 NUOwT5B5PzJiaB?= NVHHcWwxT0l3MDC9JFAvODJ|IN88US=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975 M2HhTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NYPBRlFXPzJiaB?= MVHHTVUxKD1iMD6wNlQh|ryP M4jSXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
HCC827 NV3Xfod3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NXPuToJtPzJiaB?= NWPnZlRtUUN3MDC9JFAvODJ3NDFOwG0> NHz5VIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O|YzPzJ:L3G+
HCC827 NWLmeYx6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M2XkWVczKGh? NHT3VGtKSzVyIE2gNE4xOjdizszN NEPXPJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
HCC827 NHflZ4ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1G4ZlczKGh? NUOz[ZpHUUN3MDC9JFAvODJ5IN88US=> NEnzb5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975 M3nkd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NULvZml7PzJiaB?= NVLw[IN1UUN3MDC9JFAvODNizszN MkDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{O1O|koRjJ6MEOzOVc6RC:jPh?=
H3255 MlfaSpVv[3Srb36gZZN{[Xl? NVy4R|ZFPzJiaB?= MWrHTVUxKD1iMD6wN|Mh|ryP MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255 Mmf4SpVv[3Srb36gZZN{[Xl? M4XY[VIhcA>? NGXuUoxKSzVyIE2gNE4xOzZizszN MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
NCI-H1975 M2HKdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NIrET4o4OiCq M4jr[mlEPTBiPTCwMlA1OSEQvF2= NWnHVWxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|AyQTJpPkK5O|MxOTl{PD;hQi=>
NCI-H1975 MVjGeY5kfGmxbjDhd5NigQ>? MkLlNUBp NHXhXY9KSzVyIE2gNE4xPDFizszN NX\he|NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
BAF3 NVm2eXRCTnWwY4Tpc44h[XO|YYm= M2PoVlQhcA>? NF\Me2JGSzVyIE2gNE4xPDNizszN MliyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NH7vN4s4OiCq M2fFUmlEPTBiPTCwMlA1PzJizszN NXXne5JMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O|YzPzJpPkK5OVc3Ojd{PD;hQi=>
NCI-H1975 NGW0VFlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1jCc|czKGh? MlL4TWM2OCB;IECuNFUzKM7:TR?= NWfCUXBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9 MmrCSpVv[3Srb36gZZN{[Xl? MkjjNkBp NVHUcFhVUUN3MDC9JFAvODV4IN88US=> Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
NCI-H1975 M4fxPWN6fG:2b4jpZ4l1gSCjc4PhfS=> MkDHO|IhcA>? MXjJR|UxKD1iMD6wOkDPxE1? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827 NV\ySlFiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MYLJR|UxKD1iMD6wOlE3KM7:TR?= NVG5VXdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
NCI-H1975 NFnxdJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NV[5eYN3UUN3MDC9JFAvODZ5IN88US=> M2\nelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HaCaT MYHGeY5kfGmxbjDhd5NigQ>? NUPDSJdKOyCq NXXz[m5WUUN3MDC9JFAvODd|NzFOwG0> NF7adJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN|gzQSd-Mke0N|M5Ojl:L3G+
NCI-H1975 MnjBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MX[3NkBp NF7JcJpKSzVyIE2gNE4yOyEQvF2= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431 MlflSpVv[3Srb36gZZN{[Xl? NF7GfpEyKGh? M{S4TmlEPTBiPTCwMlE1OSEQvF2= NVTwZohJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549 M3TBXmZ2dmO2aX;uJIF{e2G7 MlXCTWM2OCB;IECuNVUh|ryP NHvKNGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
Calu3 NFrNd2tEgXSxdH;4bYNqfHliYYPzZZk> MV63NkBp M4eyWWdKPTBiPTCwMlI3PCEQvF2= M3TMNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
Sf9 MkPqSpVv[3Srb36gZZN{[Xl? MmfLNlAhdWmwcx?= NE\1SplKSzVyIE2gNE4zPzhizszN MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6MkG1NUc,Ojh2OEKxOVE9N2F-
BAF3 MoizSpVv[3Srb36gZZN{[Xl? NGTCWYg4OiCq Mm\LS2k2OCB;IECuN{DPxE1? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 MXXGeY5kfGmxbjDhd5NigQ>? NIfRVoI4OiCq NVP0fIIzT0l3MDC9JFAvOzFizszN NY\STJM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H460 NYHWWmwySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NX;HbmM2PzJiaB?= M4fNd2lEPTBiPTCwMlQyPTlizszN NXLlO|h[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O|E3PjRzPD;hQi=>
LoVo NIPjdHlHfW6ldHnvckBie3OjeR?= M1:5d|IhcA>? NHz0[XhKSzVyIE2gNE41QCEQvF2= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo MYnGeY5kfGmxbjDhd5NigQ>? MoOwNkBp MnHyTWM2OCB;IECuOFgh|ryP MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NkK2O{c,Ojd7OU[yOlc9N2F-
A549 MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MXy3NkBp M{fVWWlEPTBiPTCwMlQ5PiEQvF2= NHPrOY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O|YzPzJ:L3G+
BAF3 MXjGeY5kfGmxbjDhd5NigQ>? M2nuTVczKGh? M2LjXGdKPTBiPTCwMlUh|ryP M1XtbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549 NXnxbWRrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M{jwTFczKGh? NYfvW|d[UUN3MDC9JFAvPTNizszN M4nZb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O|c{Lz5{OUS2Olc4OzxxYU6=
A549 MVHDfZRwfG:6aXPpeJkh[XO|YYm= NEmwdVM4OiCq M33MfGlEPTBiPTCwMlU{KM7:TR?= M13PcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN|QxLz5{OUi1N|M1ODxxYU6=
BAF3 MU\GeY5kfGmxbjDhd5NigQ>? MmeyO|IhcA>? MnvtS2k2OCB;IECuOVUh|ryP MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 M13MPWZ2dmO2aX;uJIF{e2G7 Mn3NO|IhcA>? NU\Gc5lkT0l3MDC9JFAvPTZizszN M3frflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HEK293 MnrrSpVv[3Srb36gZZN{[Xl? NHf2OZNKSzVyIE2gNE42PyEQvF2= M2rhUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3 NHL1e4VHfW6ldHnvckBie3OjeR?= M2KyRVczKGh? MnPrS2k2OCB;IECuOVkh|ryP M1SySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431 NFfvXZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NUn3VYkyUUN3MDC9JFAvPjF3NjFOwG0> NV;ybHhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
HT-29 MWnDfZRwfG:6aXPpeJkh[XO|YYm= NXXjO5pEPzJiaB?= Mn7YTWM2OCB;IECuOlUh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431 MYjGeY5kfGmxbjDhd5NigQ>? Mo\SPVYhcA>? NX;ub453TUN3MDC9JFAvPjZ5IN88US=> NVftZWhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
A431 NG\6WnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NVvobmhzQTZiaB?= MWPFR|UxKD1iMD62O{DPxE1? NIXQXXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
A431 M4HNU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NGPYTmc4OiCq NUHmeI5sUUN3MDC9JFAvPjh3IN88US=> NVfRRXIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A431 M1GzVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MYm5OkBp NUL1TGN5TUN3MDC9JFAvPyEQvF2= M2XtSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkCzPVkyLz5{OE[wN|k6OTxxYU6=
A549 M4nGd2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYO3NkBp NVr6eHVLUUN3MDC9JFAvQDdizszN NHLsNlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
A431 MorlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MlfGO|IhcA>? NVHqRYtTUUN3MDC9JFAvQDl|IN88US=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MU[zPUc,OjdzM{G2N|k9N2F-
BA/F3 MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MkS2O|IhcA>? MlfoTWM2OCB;IEGg{txO M4K4V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3 NGXNOoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4L5blczKGh? M2XMOWdKPTBiPTCxMlIh|ryP MlnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H2122 Ml3xSpVv[3Srb36gZZN{[Xl? NFHxc4w4OiCq M4rvNmdKPTBiPTCxMlIh|ryP M{L6flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431 MnnzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NH34b5I4OiCq NXnr[VJSUUN3MDC9JFEvOjRizszN M1\TdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
A431 NX:xdJJ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NFvCW3c4OiCq NU\RZ4w2UUN3MDC9JFEvOjZizszN NVn1VZdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|AyQTJpPkK5O|MxOTl{PD;hQi=>
A431 M{Tw[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MoTjO|IhcA>? MXLJR|UxKD1iMT62NFQh|ryP NFnmSIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzN|U4QSd-MkiwN|M2Pzl:L3G+
A549 M1;TWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MUK5OkBp M{D2dmVEPTBiPTCxMlg{KM7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
CHL MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1rlWVczKGh? NUjGSGJoT0l3MDC9JFIvQSEQvF2= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1355 MorlSpVv[3Srb36gZZN{[Xl? NHnMbFk4OiCq MnXyS2k2OCB;IEOg{txO MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1703 MW\GeY5kfGmxbjDhd5NigQ>? M1vNOVczKGh? NHTtTWtIUTVyIE2gN{42KM7:TR?= NUnFOWVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549 M3fWVWZ2dmO2aX;uJIF{e2G7 MV23NkBp NYWxW2tbT0l3MDC9JFMvPSEQvF2= NUHremJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
CHO NY\1PIRCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUS3NkBp NFS4d2JIUTVyIE2gOE4zKM7:TR?= NULLcpZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 NH7Zd41CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NVLwZ5psPzJiaB?= NUi0VItWUUN3MDC9JFQvPjFizszN MkHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BAF3 NXP4[JdUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NWHDdnZxPzJiaB?= Ml\xTWM2OCB;IEWuNVUh|ryP NY\pPWZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BEAS2B NHrJXFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NIDPcoI4OiCq M1X5cGlEPTBiPTCxOE46KM7:TR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975 MWrGeY5kfGmxbjDhd5NigQ>? NXfEeFNzOiCq MknxTWM2OCB;IEG1JO69VQ>? NEewNGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
PC9 NHK3VI9HfW6ldHnvckBie3OjeR?= MUWyJIg> MoW5TWM2OCB;IEG3JO69VQ>? NV3MT5AzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
LoVo M1zDcmZ2dmO2aX;uJIF{e2G7 NVO0bnJCOiCq MmDFTWM2OCB;IES4NEDPxE1? MmP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975 NHfWdYZCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= M2j2OWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOi53IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s NH7JW409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
rat hepatocytes M{\iVGZ2dmO2aX;uJIF{e2G7 MmGwTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK|Yh[2WubIO= Ml3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
human hepatocytes MnLCSpVv[3Srb36gZZN{[Xl? MVzJcpRzcW6|aXOgZ4xm[XKjbnPlJIlvKGi3bXHuJIhmeGG2b3P5eIV{KG2nYYP1doVlKHCncjCxNEc3KGOnbHzz NXXCRnQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
NCI-H1975 MVPBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl? M2G5dGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPSCvZz;r[{9l[XluIIDvJJFlKG[xcjC3JIRigXNicnXsZZRqfmVidH:gZ49vfHKxbB?= M13xUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975 MWXGeY5kfGmxbjDhd5NigQ>? NHSxdZRU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhTUeIUjDUO|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHSxIFnDOVAh\m:{IIfpcIQhfHmyZTDFS2ZTKGW6cILld5NqdmdiaIXtZY4hSTR|MTDj[Yxtew>? M2WwN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
NCI-H1975 M3vNOGFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?= MkXuRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWiCWN{mwUU9NQDV6UjDkc5VjdGVibYX0ZY51KGW6cILld5NqdmdiaIXtZY4hVkOLLVixPVc2KGOnbHzzJJhmdm:pcnHmeIVlKGmwIFLBUGIw[yCjdHj5cYlkKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhdWdxa3esJJBwKGKrZDDmc5IhOjFiZHH5dy=> NWfvNnNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|AyQTJpPkK5O|MxOTl{PD;hQi=>
HCC827 NHPFfndCeG:ydH;zbZMh[XO|YYm= NFSxXWpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIViemy7IHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCxMlM1LSl? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
HCC827 MYjBdI9xfG:|aYOgZZN{[Xl? Mkn1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0Ok1CPzVyIHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDsZZRmKGGyb4D0c5Rq[yClZXzsd{BifCB|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSB{Nz6xOEUq MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
A549 NVrQOVlsTnWwY4Tpc44h[XO|YYm= MnzxV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gRVU1QSClZXzsd{BmgHC{ZYPzbY5oKHerbHSteJlx\SCHR1\SM2suWmG|IH31eIFvfCC2bzDJR|UxKG[xcjDoeY1idiCQQ1mtTFE6PzViY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboS= NH3yfYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
HCC827 NIPjXWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1\jTlczKGh? MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{iyO{Bk\WyuczDheEAyKHWPIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?= MoTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO|IoRjJ7NUe2NlczRC:jPh?=
BAF3 NFL0TIdHfW6ldHnvckBie3OjeR?= NXTodIhKOiCq M1TxZmlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;MPFU5Wi:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M{CzUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
BAF3 MoLqSpVv[3Srb36gZZN{[Xl? MVOyJIg> M1\P[WlvcGmkaYTpc44hd2ZiRVfGVkAyQURxVEe5NG0wSzd7N2OgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFXHSk1qdmS3Y3XkJJJm[2WydH;yJJBpd3OyaH;yfYxifGmxbjDheEAyKHSxIEOgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36g[o9zKDF3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NHzo[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
NCI-H1975 MlTFRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7 MY\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhgGWwb3fyZYZ1\WRiaX6gV3RQS0tvRn;4clFvfS:QaoWgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCyNEBu\y:tZz;kZZktKHCxIIHkJIZweiBzNDDkZZl{KHKnbHH0bZZmKHSxIIXueJJm[XSnZDDjc451em:u NEjadW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIyQSd-MkizPVUzOTl:L3G+
Caco2 MlK1SpVv[3Srb36gZZN{[Xl? NUjh[mxNOiCq MlrESYZndHW6IILheIlwKG:oIHHwdIFz\W62IIDldo1m[WKrbHn0fUBnem:vIHLhd49t[XSncnHsJJNq\GVidH:gZZBq[2GuIIPp[IUhd3[ncjDhdIlk[Wxic3nk[UB1dyCkYYPvcIF1\XKjbDDzbYRmKG:4ZYKgbY4hcHWvYX6gR4FkdzJiY3XscJMh[XRiNTD1UUBqdmO3YnH0[YQh\m:{IEKgbJJ{ MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
A431 M{G3[mZ2dmO2aX;uJIF{e2G7 MWTT[Yxm[3Srdnn0fUBz[XSrbzDv[kBGSzVyIH\vdkBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKgeI8hTUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy|IHjhdoJwemmwZzDFS2ZTNUx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ> NHiyOJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
Caco2 M2n0SGZ2dmO2aX;uJIF{e2G7 MV6yJIg> Ml65RZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG|b3zheIVz[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
Caco2 MXzGeY5kfGmxbjDhd5NigQ>? MUeyJIg> Mkf1RZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{Bj[XOxbHH0[ZJidCC2bzDhdIlk[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN? M2nadVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
NCI-H1975 Mn\RSpVv[3Srb36gZZN{[Xl? NEmw[Vg1KGh? NHLvdnBKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRYt1KHCqb4PwbI9zgWyjdHnvckBifCCWaIKzNFgwW2W{NEezJJNqfGViYYSgNUB2VSCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NIntPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 M2fSZ2Z2dmO2aX;uJIF{e2G7 M2nicVQhcA>? MXPJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 MnrKRZBweHSxc3nzJIF{e2G7 NX7OcmZnPDhiaB?= NEnDcIJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO|kxVSCvdYThcpQh[XO|ZYPz[YQh[XNiY3HzdIF{\TNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 MnLSRZBweHSxc3nzJIF{e2G7 MV:0PEBp MnX5TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO|ZYPz[YQh[XNiY3HzdIF{\S1|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n M2fU[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9 MVHBdI9xfG:|aYOgZZN{[Xl? NIPFUIY1QCCq M{jhXmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?= MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255 M13pOmFxd3C2b4Ppd{Bie3OjeR?= NYG2e|dXPDhiaB?= M{HoNWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSEOyOVUh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIhdXW2YX70JIF{e2W|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?= MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 NVnv[HRMSXCxcITvd4l{KGG|c3H5 MnuyOFghcA>? MXTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBufXSjboSgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> NHm2RXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9 M3XhPWFxd3C2b4Ppd{Bie3OjeR?= NEDaTWM1QCCq NFjVUGdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 NVnUUY1MSXCxcITvd4l{KGG|c3H5 M1jGO|Q5KGh? NHfXdVBKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDlfI9vKDF7IHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDQRXJRKGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK|IHL5JIludXWwb3Lsc5R1cW6p Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255 NU[5bVN5SXCxcITvd4l{KGG|c3H5 Ml\4OFghcA>? MULJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh|MkW1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n M{P5dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 M2nwWGZ2dmO2aX;uJIF{e2G7 MWLT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEB1dyCLQ{WwJIZweiCqdX3hckBCPDNzIHPlcIx{KGijcnLvdolv\yC5aXzkMZR6eGViRVfGVi=> NIPKU|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
human hepatocytes NFPX[HdHfW6ldHnvckBie3OjeR?= M1rFZmlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5iaIXtZY4hcGWyYYTvZ5l1\XNiYYPz[ZN{\WRicHXyJI1qdGyrb36gZ4VtdHN? NVHj[Iw1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
rat hepatocytes NIe5N2dHfW6ldHnvckBie3OjeR?= M37WWWlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{ MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
A549, NCI-H1975 Ml[xSpVv[3Srb36gZZN{[Xl? MmH4V4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{ NFzq[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
A549, PC9 MUjGeY5kfGmxbjDhd5NigQ>? MlK4V4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIHTlcIV1cW:wIH31eIFvfCCrbjDoeY1idiCSQ{mgZ4VtdHN? M1PsWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827 MX;BdI9xfG:|aYOgZZN{[Xl? NVz2UFJEUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO|UxKGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCnYYLsfUBieG:ydH;0bYMh[2WubIOgZZQhOyC3TTDh[pRmeiB{NDDodpMh[nliQX7u[ZhqdiCYLV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgSBqUo\iJF0hOS5|NDD0c{AyNjZ5JTm= M3;VPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN|QxLz5{OUi1N|M1ODxxYU6=
NCI-H1975 NH3XS3JHfW6ldHnvckBie3OjeR?= NVLWTGM3UW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCjdDCxJJRwKDFyMDDuUUBjgSCZZYP0[ZJvKGKub4SgcYV1cG:m MnvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7ME[xNVQoRjJ7OUC2NVE1RC:jPh?=
A431 Mn\kSpVv[3Srb36gZZN{[Xl? MVnT[Yxm[3Srdnn0fUBz[XSrbzygdoF1cW9iSVO1NEBnd3JiaIXtZY4hSTR|MTDj[YxteyCxdnXy[ZhxemW|c3nu[{B4cWymLYT5dIUhTUeIUjD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNM2w5PTiUIH31eIFvfA>? M{G3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxOlM6Lz5{N{GzNVY{QTxxYU6=
PC9 NH\NTJVCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= MUjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
A431 MYHBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl? NGG4S3hCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPSCvZz;r[{9l[XluIIDvJJFlKG[xcjC3JIRigXNicnXsZZRqfmVidH:gZ49vfHKxbB?= MmLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-EGFR / p-AKT / p-ERK; 

PubMed: 28416483     


PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib.

ABCB1; 

PubMed: 27649127     


The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.

28416483 27649127
Growth inhibition assay
Cell viability; 

PubMed: 31043587     


Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. *P < 0.05, **P < 0.01, ***P < 0.005 by t-test.

31043587
Immunofluorescence
Ki67 / γH2AX / p16; 

PubMed: 29212784     


PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. **P ≤ 0.01, ***P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.

29212784
体内試験 AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]

お薦めの試験操作(参考用のみ)

動物試験:

[2]

- 合併
  • 動物モデル: Mice bearing PC9 and H1975 xenograft tumors
  • 投薬量: ~5 mg/kg
  • 投与方法: p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 99 mg/mL (198.15 mM) warming
Water Insoluble
Ethanol '43 mg/mL warmed '43
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
混合させたのち直ちに使用することを推奨します。
7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 499.61
化学式

C28 H33 N7 O2

CAS No. 1421373-65-0
Storage powder
in solvent
別名 Mereletinib
Smiles CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02841579 Completed Drug: Osimertinib Non-Small Cell Lung Cancer MedSIR|AstraZeneca August 2016 Phase 2
NCT02771314 Unknown status Drug: AZD9291 Non Small Cell Lung Cancer Hellenic Oncology Research Group August 2 2016 Phase 2
NCT02529995 Completed Drug: AZD9291 40 mg|Drug: AZD9291 80 mg Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive AstraZeneca August 24 2015 Phase 1
NCT02491944 Completed Drug: AZD9291|Drug: [14C]AZD9291 Oncology AstraZeneca July 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

  • 回答:

    Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Tags: Osimertinib (AZD9291)を買う | Osimertinib (AZD9291) ic50 | Osimertinib (AZD9291)供給者 | Osimertinib (AZD9291)を購入する | Osimertinib (AZD9291)費用 | Osimertinib (AZD9291)生産者 | オーダーOsimertinib (AZD9291) | Osimertinib (AZD9291)化学構造 | Osimertinib (AZD9291)分子量 | Osimertinib (AZD9291)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID